^
Association details:
| Biomarker: | EP300 mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | R-CHOP (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
018 | INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY
Published date:
06/09/2021
Excerpt:
...141 DLBCL patients received R-CHOP14 immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone every 2 weeks)….The presence of mutations of SOCS1, without mutations in CREBBP and EP300, defined a group of patients with favorable prognosis with a 5-year progression-free survival (PFS) rate of 100%, while patients harboring mutations in CREBBP or EP300 or with SOCS1 wild-type had a 5-year PFS of 69% (p = 0.025).
Trial ID:
